- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02723617
The Dose-Response Effects of Lean Beef in a Mediterranean-Style Dietary Pattern on Cardiovascular Disease Risk Factors
April 29, 2019 updated by: David Baer, USDA Beltsville Human Nutrition Research Center
The objective of this study is to evaluate the effects of different quantities of lean beef (0.5, 2.5, 5.5 oz/day) on lipids, lipoproteins, and vascular health endpoints in the context of a modified Mediterranean dietary pattern that is representative of foods typically consumed in the United States.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The DASH (Dietary Approaches to Stop Hypertension) dietary pattern, the USDA Food Pattern, and the American Heart Association (AHA) Diet are all recommended for the reduction of LDL-C and blood pressure, two major risk factors for cardiovascular disease (CVD).
The recommended food-based dietary patterns emphasize consumption of vegetables, fruits and whole grains; include low-fat dairy products, poultry, fish, legumes, non-tropical vegetable oils and nuts; and limit intake of sweets, sugar-sweetened beverages and red meats.
The Mediterranean dietary pattern has gained widespread popularity because of an impressive evidence base showing health benefits in the prevention of many chronic diseases including CVD.
The Mediterranean Diet Pyramid recommends that red meat be consumed less than 2 servings per week, with an emphasis on lean cuts.
However, as the BOLD (Beef in an Optimal Lean Diet) study has demonstrated, lean beef can be included in a heart healthy dietary pattern that achieves both low density lipoprotein and blood pressure-lowering effects.
The BOLD study utilized beef consumption levels of 4 or 5.4 ounces of lean beef daily, which is significantly higher than the American average of app. 3 ounces per day.
This study will evaluate three levels of beef in the context of a Mediterranean diet, compared to an Average American diet.
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Beltsville, Maryland, United States, 20705
- USDA-ARS, Beltsville Human Nutrition Research Center
-
-
Pennsylvania
-
University Park, Pennsylvania, United States, 16802
- Penn State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Body Mass Index between 20 and 40 kg/m2
- Non-smoker
- Fasting glucose ≤ 126 mg/dl
Exclusion Criteria:
- Low HDL-C (<15th percentile of US population)
- Use of cholesterol lowering medications
- Elevated blood pressure (systolic blood pressure > 160 mm Hg and diastolic blood pressure > 100 mm Hg) or use of medication to treat hypertension for less than 6 months
- Elevated triglycerides ( > 350 mg/dL)
- Active cardiovascular disease (such as a heart attack or procedure within the past six months or participation in a cardiac rehabilitation program within the last six months, stroke, or history/treatment for transient ischemic attacks in the past six months, or documented history of pulmonary embolus in the past six months)
- Presence of kidney disease, liver disease, gout, untreated or unstable hyper- or hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other metabolic diseases, or malabsorption syndromes
- Women who have given birth during the previous 12 months
- Pregnant women or women who plan to become pregnant or become pregnant during the study
- Lactating women
- Weight loss of ≥ 10% of body weight within 6 months prior to enrolling in the study
- Smokers or use of any tobacco products in past 6 months
- Known (self-reported) allergy or adverse reaction to study foods
- History of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets)
- Unable or unwilling to give informed consent or communicate with study staff
- Self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)
- Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: MED 0.5
|
Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
|
Other: MED 2.5
|
Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
|
Other: MED 5.5
|
Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
|
Other: AAD 2.5
|
Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lipid/lipoprotein profile will be measured in blood
Time Frame: Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
The following will be measured in the blood on 2 consecutive days at baseline (start of trial) and the end of each 4-week diet period: lipids and lipoproteins, apolipoproteins, lipoprotein particle number/size, and proprotein convertase subtilisin/kexin type 9 (PCSK9).
|
Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulse Wave will be measured using Sphygmocor EXCEL
Time Frame: Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Pulse wave analysis and pulse wave velocity will be conducted.
|
Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Markers of vascular health will be measured in blood
Time Frame: Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Adhesion molecules and endothelin-1 will be measured in the blood.
|
Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Systemic inflammation will be measured in blood
Time Frame: Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Markers of systemic inflammation will be measured, such as fibrinogen, IL-6, TNF-alpha, serum amyloid A, and CRP.
|
Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Fecal microbiota will be analyzed
Time Frame: Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Feces will be analyzed for bacterial typing.
|
Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Measures of oxidative stress will be measured in urine
Time Frame: Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Urinary 8-iso-PGF-2α and urinary 15-keto-dihydro- PGF-2α will be measured.
|
Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Blood glucose, serum insulin, and insulin c-peptide will be measured.
Time Frame: Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Blood glucose and serum insulin and insulin c-peptide will be measured.
|
Week 0, end of diet period 1 (week 4), end of diet period 2 (week 9), end of diet period 3 (week 15), end of diet period 4 (week 21)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 25, 2016
Primary Completion (Actual)
May 16, 2018
Study Completion (Actual)
May 16, 2018
Study Registration Dates
First Submitted
March 23, 2016
First Submitted That Met QC Criteria
March 23, 2016
First Posted (Estimate)
March 30, 2016
Study Record Updates
Last Update Posted (Actual)
May 1, 2019
Last Update Submitted That Met QC Criteria
April 29, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- HS54
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on MED 0.5
-
National Institute of Hygiene and Epidemiology,...Ministry of Health, Vietnam; Ministry of Science and Technology, VietnamCompleted
-
Rambam Health Care CampusCompleted
-
Pulse TherapeuticsSuspendedCerebrovascular Disorders | Neurologic Disorder | Infarction, Middle Cerebral Artery | Stroke, Ischemic | Stroke, Acute | Intracranial Embolism and Thrombosis | Strokes ThromboticUnited Kingdom
-
University of North Carolina, Chapel HillCenters for Disease Control and PreventionActive, not recruiting
-
South Eastern Health and Social Care TrustCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
USDA Grand Forks Human Nutrition Research CenterEgg Nutrition CenterTerminated
-
Taipei Veterans General Hospital, TaiwanNational Yang Ming Chiao Tung UniversityRecruitingMild Cognitive Impairment (MCI) | Oral Health | Mediterranean DietTaiwan
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Queen's University, BelfastWellcome TrustCompletedSubjective Cognitive ImpairmentUnited Kingdom
-
Istanbul UniversityUnknown